These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24051396)

  • 1. The development speed paradox: can increasing development speed reduce R&D productivity?
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2014 Mar; 19(3):209-14. PubMed ID: 24051396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 3. The paradox of scientific excellence and the search for productivity in pharmaceutical research and development.
    Grasela TH; Slusser R
    Clin Pharmacol Ther; 2014 May; 95(5):521-7. PubMed ID: 24458012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for entrepreneurship in R&D in the pharmaceutical industry.
    Douglas FL; Narayanan VK; Mitchell L; Litan RE
    Nat Rev Drug Discov; 2010 Sep; 9(9):683-9. PubMed ID: 20725093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A better prescription for drug-development financing.
    Kessel M; Frank F
    Nat Biotechnol; 2007 Aug; 25(8):859-66. PubMed ID: 17687358
    [No Abstract]   [Full Text] [Related]  

  • 10. Can quantitative pharmacology improve productivity in pharmaceutical research and development?
    Patel M; Bueters T
    Expert Opin Drug Discov; 2020 Oct; 15(10):1111-1114. PubMed ID: 32511018
    [No Abstract]   [Full Text] [Related]  

  • 11. Do large mergers increase or decrease the productivity of pharmaceutical R&D?
    Ringel MS; Choy MK
    Drug Discov Today; 2017 Dec; 22(12):1749-1753. PubMed ID: 28646641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driving external chemistry optimization via operations management principles.
    Bi FC; Frost HN; Ling X; Perry DA; Sakata SK; Bailey S; Fobian YM; Sloan L; Wood A
    Drug Discov Today; 2014 Mar; 19(3):289-94. PubMed ID: 23973340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-centered drug discovery as the means to improved R&D productivity.
    Raoof AA; Aerssens J
    Drug Discov Today; 2015 Sep; 20(9):1044-8. PubMed ID: 25908579
    [No Abstract]   [Full Text] [Related]  

  • 14. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helping science to succeed: improving processes in R&D.
    Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
    Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharma business models in Canada.
    March-Chordà I; Yagüe-Perales RM
    Drug Discov Today; 2011 Aug; 16(15-16):654-8. PubMed ID: 21708279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.